NLNK NewLink Genetics Corporation

10.18
+0.02  (0%)
Previous Close 10.16
Open 10.17
Price To book 3.09
Market Cap 317839522
Shares 31,221,957
Volume 1,417,400
Short Ratio 1.37
Av. Daily Volume 3,291,833

SEC filingsSee all SEC filings

  1. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171127952
  2. 8-K - Current report 171120351
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171120350
  4. 8-K - Current report 171117926
  5. 424B5 - Prospectus [Rule 424(b)(5)] 171117917

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data presented at ASCO June 4, 2017. Abstract 105.
GDC-0919 and atezolizumab
Solid tumors
Phase 2 poster presentation at ASCO June 5, 2017.
Indoximod + Sipuleucel-T
Metastatic castration resistant prostate cancer (mCRPC)
Phase 2 interim analysis released at AACR meeting April 4, 2017. Updated data released September 7, 2017 showed improvement in Complete Response (CR) to 20% (10/51 patients) compared to CR of 12% (6/51 patients).
Indoximod in combination with KEYTRUDA
Melanoma - cancer
Phase 2 data due 2H 2017.
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 3 failed to meet primary endpoint - May 2016
HyperAcute Pancreas - IMPRESS
Surgically resected pancreatic cancer
Phase 3 failed to show improvement in survival.
HyperAcute Pancreas - PILLAR
Pancreatic cancer
Enrolling
Indoximod +Tergenpumatucel-L
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet endpoints - noted June 2, 2017.
Indoximod + taxane
Cancer - breast

Latest News

  1. ETFs with exposure to NewLink Genetics Corp. : October 16, 2017
  2. Bank Of America Sees NewLink Genetics As 'Undervalued'
  3. The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September
  4. Here's Why NewLink Genetics Corp. Stock Is Surging Again Today
  5. Before You Invest In NewLink Genetics Corporation (NLNK), Consider This Factor
  6. Today's Research Reports on Trending Tickers: Anthera Pharmaceuticals and NewLink Genetics
  7. NewLink Genetics Prices Public Offering of Common Stock
  8. Edited Transcript of NLNK earnings conference call or presentation 28-Jul-17 12:30pm GMT
  9. NewLink Genetics Announces Proposed Public Offering of Common Stock
  10. NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic Cancer
  11. 3 Small-Cap Biotech Stocks to Buy This Fall
  12. ETFs with exposure to NewLink Genetics Corp. : September 19, 2017
  13. NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
  14. Analyst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside
  15. NewLink Genetics (NLNK) Jumps: Stock Rises 29.9%
  16. 3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
  17. Why NewLink Genetics, Zumiez, and Everest Re Group Jumped Today
  18. Why NewLink Genetics Is Soaring 37.5% Higher Today

SEC Filings

  1. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171127952
  2. 8-K - Current report 171120351
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171120350
  4. 8-K - Current report 171117926
  5. 424B5 - Prospectus [Rule 424(b)(5)] 171117917
  6. 8-K - Current report 171098563
  7. SC 13G - Statement of acquisition of beneficial ownership by individuals 171083481
  8. 8-K - Current report 171072879
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171004712
  10. 8-K - Current report 17988005